Safety and pharmokinetics of triamcinolone hexacetonide in rabbit eyes.

Published

Journal Article

PURPOSE: The aim of this study was to evaluate whether intravitreal triamcinolone hexacetonide (TH) is a safe, longer lasting alternative to intravitreal triamcinolone acetonide (TA) in the rabbit eye. METHODS: Three groups, each comprising of 15 Dutch-belted rabbits, received a unilateral injection of 0.1 mL of drug and 0.1 mL of physiologic salt solution in the fellow eye. Group I received TA, group II received commercially available TH, and group III received reformulated iso-osmolar triamcinolone hexacetonide (rTH). Simultaneous bilateral dark-adapted electroretinography was performed following the injection. Retinal morphology was assessed by using histopathology in each group enucleated 12 weeks after injection. High-performance liquid chromatography of vitreous isolated from the enucleated eyes was used to determine drug concentrations. RESULTS: A significant reduction in saturated a-wave and maximal scotopic b-wave was observed in the group II eyes relative to the fellow control eyes at both 2 and 12 weeks postinjection (P < 0.001 for each comparison) but not in the other groups. Histopathology showed no differences between drug-injected eyes and fellow control eyes in groups I and III, but in group II there was severe degeneration of all retina layers. In group I, the drug half-life was 17.7 +/- 1.7 days, group II 44 +/- 13 days, and group III 12.8 +/- 2.3 days. CONCLUSIONS: The half-life of commercially available TH in the vitreous is double that of TA, but the former is toxic to the retina in this rabbit model. Reformulated iso-osmolar TH showed no evidence of deleterious effects to retina function or structure but had a similar half-life to TA.

Full Text

Duke Authors

Cited Authors

  • Abd-El-Barr, MM; Albini, TA; Carvounis, PE; He, F; Manzano, RPA; Chevez-Barrios, P; Wensel, TG; Wu, SM; Holz, ER

Published Date

  • April 2008

Published In

Volume / Issue

  • 24 / 2

Start / End Page

  • 197 - 205

PubMed ID

  • 18355133

Pubmed Central ID

  • 18355133

International Standard Serial Number (ISSN)

  • 1080-7683

Digital Object Identifier (DOI)

  • 10.1089/jop.2007.0103

Language

  • eng

Conference Location

  • United States